Novo Nordisk A/S (NYSE:NVO) Trading Down 0.6% – Should You Sell?

Novo Nordisk A/S (NYSE:NVO)’s share price fell 0.6% during mid-day trading on Monday . The stock traded as low as $117.07 and last traded at $117.33. 826,078 shares changed hands during trading, a decline of 81% from the average session volume of 4,275,844 shares. The stock had previously closed at $118.09.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on NVO shares. BMO Capital Markets cut their target price on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Thursday, October 10th. Finally, StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 9th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $144.50.

Novo Nordisk A/S Trading Down 0.6 %

The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.46. The stock’s fifty day moving average price is $127.89 and its two-hundred day moving average price is $131.61. The stock has a market capitalization of $519.39 billion, a P/E ratio of 39.49, a price-to-earnings-growth ratio of 1.54 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, August 7th. The company reported $0.65 EPS for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. The business had revenue of $9.82 billion for the quarter, compared to the consensus estimate of $9.91 billion. Equities research analysts forecast that Novo Nordisk A/S will post 3.01 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a semi-annual dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 16th were given a dividend of $0.5126 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a yield of 0.7%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 24.66%.

Institutional Investors Weigh In On Novo Nordisk A/S

Hedge funds have recently added to or reduced their stakes in the stock. 1620 Investment Advisors Inc. bought a new stake in shares of Novo Nordisk A/S in the second quarter worth approximately $25,000. Gilliland Jeter Wealth Management LLC increased its position in Novo Nordisk A/S by 200.0% during the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after acquiring an additional 120 shares during the last quarter. Strategic Investment Solutions Inc. IL bought a new position in Novo Nordisk A/S in the second quarter valued at about $25,000. Dixon Mitchell Investment Counsel Inc. purchased a new position in Novo Nordisk A/S in the first quarter worth about $26,000. Finally, Orion Capital Management LLC bought a new stake in shares of Novo Nordisk A/S during the 1st quarter valued at about $26,000. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.